He Kun, Liu Ping, Xu Lisa X
Med-X Research Institute, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.
Cell Death Dis. 2017 Mar 23;8(3):e2703. doi: 10.1038/cddis.2017.125.
Tumor metastasis is a major concern in tumor therapy. In our previous studies, a novel tumor therapeutic modality of the cryo-thermal therapy has been presented, highlighting its effect on the suppression of distal metastasis and leading to long-term survival in 4T1 murine mammary carcinoma model. To demonstrate the therapeutic efficacy in other aggressive tumor models and further investigate the mechanism of long-term survival induced, in this study, spontaneous metastatic murine B16F10 melanoma model was used. The cryo-thermal therapy induced regression of implanted melanoma and prolonged long-term survival while inhibiting lung metastasis. It also promoted the activation of CD4 CD25 conventional T cells, while reduced the percentage of CD4 CD25 regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in the spleen, lung and blood. Furthermore, the cryo-thermal therapy enhanced the cytolytic function of CD8 T cells and induced differentiation of CD8 T cells into memory stem T cell (T), and differentiation of CD4 T cells into dominant CD4-CTL, Th1 and Tfh subsets in the spleen for 90 days after the treatment. It was found that good therapeutic effect was mainly dependent on CD4 T cells providing a durable memory antitumor immune response. At the same time, significant increase of serum IFN-γ was also observed to provide an ideal microenvironment of antitumor immunity. Further study showed that the rejection of re-challenge of B16F10 but not GL261 tumor in the treated mice in 45 or 60 days after the treatment, implied a strong systemic and melanoma-specific memory antitumor immunity induced by the treatment. Thus the cryo-thermal therapy would be considered as a new therapeutic strategy to prevent tumor recurrence and metastasis with potential clinical applications in the near future.
肿瘤转移是肿瘤治疗中的一个主要问题。在我们之前的研究中,提出了一种新型的肿瘤治疗方法——冷冻热疗法,突出了其对抑制远端转移的作用,并在4T1小鼠乳腺癌模型中实现了长期存活。为了证明该疗法在其他侵袭性肿瘤模型中的治疗效果,并进一步研究其诱导长期存活的机制,本研究使用了自发转移的小鼠B16F10黑色素瘤模型。冷冻热疗法可使植入的黑色素瘤消退,延长长期生存期,同时抑制肺转移。它还促进了CD4 CD25常规T细胞的活化,同时降低了脾脏、肺和血液中CD4 CD25调节性T细胞(Tregs)和髓系来源抑制细胞(MDSCs)的百分比。此外,冷冻热疗法增强了CD8 T细胞的细胞溶解功能,并诱导CD8 T细胞分化为记忆性干细胞T细胞(T),以及在治疗后90天内使脾脏中的CD4 T细胞分化为主导性CD4-CTL、Th1和Tfh亚群。研究发现,良好的治疗效果主要依赖于CD4 T细胞提供持久的记忆性抗肿瘤免疫反应。同时,还观察到血清IFN-γ显著增加,为抗肿瘤免疫提供了理想的微环境。进一步研究表明,治疗后45或60天,治疗组小鼠对B16F10而非GL261肿瘤再次攻击的排斥反应,意味着该治疗诱导了强大的全身性和黑色素瘤特异性记忆性抗肿瘤免疫。因此,冷冻热疗法将被视为一种预防肿瘤复发和转移的新治疗策略,在不久的将来具有潜在的临床应用价值。